A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin

Publisher： Bentham Science Publishers

E-ISSN： 1875-6182|13|2|105-112

ISSN： 1871-5257

Source： Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol.13, Iss.2, 2015-08, pp. : 105-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 11, Iss. 3, 2013-09 ,pp. : 203-206

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?

By  

Current Vascular Pharmacology, Vol. 14, Iss. 6, 2016-10 ,pp. : 494-497

Bentham Science Publishers

Access to resources Recommend Favorite

A Systematic Review on Effect of Canagliflozin in Special Population

By  

Current Diabetes Reviews, Vol. 12, Iss. 3, 2016-07 ,pp. : 211-222

Bentham Science Publishers

Access to resources Recommend Favorite

Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

By  

Digestive Diseases, Vol. 35, Iss. 3, 2017-03 ,pp. : 267-274

Karger

Access to resources Recommend Favorite

Canagliflozin for the treatment of adults with Type 2 diabetes

By Aschner Pablo J  

Diabetes Management, Vol. 3, Iss. 4, 2013-07 ,pp. : 343-350

Future Medicine

Access to resources Recommend Favorite